# A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct07303803` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07303803](<https://clinicaltrials.gov/study/NCT07303803>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07303803

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT07303803. Randomized; quadruple masking; primary purpose treatment. Start 2026-01-01 (actual); primary completion 2030-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT07303803, source copy `cardio:ctgov-nct07303803-2026-06-03`, retrieved 2026-10-26)
- Started: 2026-01-01 (actual) (ClinicalTrials.gov record NCT07303803, source copy `cardio:ctgov-nct07303803-2026-06-03`, retrieved 2026-10-26)
- Primary completion: 2030-12-01 (anticipated) (ClinicalTrials.gov record NCT07303803, source copy `cardio:ctgov-nct07303803-2026-06-03`, retrieved 2026-10-26)
- Completion: 2030-12-01 (anticipated) (ClinicalTrials.gov record NCT07303803, source copy `cardio:ctgov-nct07303803-2026-06-03`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07303803, source copy `cardio:ctgov-nct07303803-2026-06-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07303803-2026-06-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
- Acronym: CHIG-MASH
- Condition: MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Condition: T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug): Chiglitazar Placebo
- Intervention (Drug): Chiglitazar
- Intervention (Drug): vitamin E
- Intervention (Drug): Polyene Phosphatidyl choline
- Lead sponsor: Shanghai Jiao Tong University School of Medicine
- Lead sponsor class: OTHER
- Collaborator: Chipscreen Biosciences, Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Shanghai Jiao Tong University School of Medicine (`cardio:org-shanghai-jiao-tong-university-school-of-medicine`)
- Registry lists this organization as a collaborator: Chipscreen Biosciences, Ltd. (`cardio:org-chipscreen-biosciences-ltd`)

## Provenance

Content hash: a1c8234d10c8d22524688a4da53ae497d21f7e3f562923006efba2e41a6d2f0f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
